Literature DB >> 9839146

The comorbidity of alcohol dependence and affective disorders: treatment implications.

M T Lynskey1.   

Abstract

This paper reviews recent literature on the prevalence of alcohol dependence and affective disorders (major depression, dysthymia), the comorbidity of these conditions and the effects of comorbid affective disorders on the outcome of treatment for alcohol dependence. Alcohol dependence and affective disorders co-occur at significantly higher rates than would be expected by chance within the general population. This comorbidity is further elevated in samples of people seeking treatment for alcohol dependence, suggesting that the co-occurrence of affective disorders may be an important determinant of treatment seeking. The results of a number of recent placebo-controlled studies have suggested that pharmacological treatment with anti-depressants may enhance the efficacy of treatment for alcohol dependence in individuals with comorbid affective disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839146     DOI: 10.1016/s0376-8716(98)00095-7

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  32 in total

1.  Agitated depression in substance dependence.

Authors:  Adam M Leventhal; Joel Gelernter; David Oslin; Raymond F Anton; Lindsay A Farrer; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2011-01-31       Impact factor: 4.492

2.  Comparing barriers to mental health treatment and substance use disorder treatment among individuals with comorbid major depression and substance use disorders.

Authors:  Ramin Mojtabai; Lian-Yu Chen; Christopher N Kaufmann; Rosa M Crum
Journal:  J Subst Abuse Treat       Date:  2013-08-29

3.  Racial Differences in the Transactional Relationship Between Depression and Alcohol Use From Elementary School to Middle School.

Authors:  Erica L Birkley; Tamika C B Zapolski; Gregory T Smith
Journal:  J Stud Alcohol Drugs       Date:  2015-09       Impact factor: 2.582

4.  Mediated and moderated effects of neurocognitive impairment on outcomes of treatment for substance dependence and major depression.

Authors:  Matthew J Worley; Susan R Tate; Eric Granholm; Sandra A Brown
Journal:  J Consult Clin Psychol       Date:  2014-03-03

5.  Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.

Authors:  Doug Hyun Han; Sun Mi Kim; Jung Eun Choi; Kyung Joon Min; Perry F Renshaw
Journal:  J Psychopharmacol       Date:  2013-01-16       Impact factor: 4.153

6.  Abstinence following alcohol drinking produces depression-like behavior and reduced hippocampal neurogenesis in mice.

Authors:  Jennie R Stevenson; Jason P Schroeder; Kimberly Nixon; Joyce Besheer; Fulton T Crews; Clyde W Hodge
Journal:  Neuropsychopharmacology       Date:  2008-06-18       Impact factor: 7.853

7.  Ketamine administration during a critical period after forced ethanol abstinence inhibits the development of time-dependent affective disturbances.

Authors:  Oliver Vranjkovic; Garrett Winkler; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2018-05-24       Impact factor: 7.853

Review 8.  Exercise training - A beneficial intervention in the treatment of alcohol use disorders?

Authors:  Mark Stoutenberg; Chad D Rethorst; Olivia Lawson; Jennifer P Read
Journal:  Drug Alcohol Depend       Date:  2015-11-22       Impact factor: 4.492

9.  CLOCK is suggested to associate with comorbid alcohol use and depressive disorders.

Authors:  Louise K Sjöholm; Leena Kovanen; Sirkku T Saarikoski; Martin Schalling; Catharina Lavebratt; Timo Partonen
Journal:  J Circadian Rhythms       Date:  2010-01-21

10.  Prevalence of alcohol consumption and hazardous drinking, tobacco and drug use in urban Tanzania, and their associated risk factors.

Authors:  Joseph Mbatia; Rachel Jenkins; Nicola Singleton; Bethany White
Journal:  Int J Environ Res Public Health       Date:  2009-07-16       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.